Tirzepatide Mechanism and Clinical Use

Introduction to Tirzepatide

Tirzepatide is a first-in-class dual receptor agonist that acts on both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, providing superior glycemic control and weight reduction compared to single-target GLP-1 receptor agonists 1, 2

Tirzepatide stimulates glucose-dependent insulin secretion from pancreatic β-cells, inhibits glucagon secretion in hyperglycemic states, delays gastric emptying, and promotes satiety through central nervous system pathways through its GLP-1 receptor activity 1, 3
Tirzepatide activates GIP receptors, enhancing insulin secretion in response to rising glucose levels, augmenting glucagon secretion during euglycemia/hypoglycemia, and inhibiting glucagon secretion during hyperglycemia 1

Tirzepatide is administered via subcutaneous injection once weekly 2
Tirzepatide has a modified structure to prevent rapid inactivation by dipeptidyl peptidase-4 (DPP-4) 1
Tirzepatide is typically initiated at lower doses and titrated upward to minimize gastrointestinal side effects 1

The FDA has approved tirzepatide for chronic weight management in adults with obesity or overweight with weight-related comorbidities 2
Tirzepatide produces significant weight loss, with 15% mean weight loss at 72 weeks with the 5 mg dose, 19.5% with the 10 mg dose, and 20.9% with the 15 mg dose (compared to 3.1% with placebo) 2
Tirzepatide has a favorable cardiovascular safety profile, according to a meta-analysis of clinical trials 2

Gastrointestinal effects are the most common side effects, including nausea, vomiting, dyspepsia, diarrhea, constipation, and gastrointestinal reflux 1
Tirzepatide should be avoided in patients with gastroparesis due to its effects on gastric emptying 1
Patients should be monitored for cardiac arrhythmia/tachycardia, especially those who are susceptible 1
Long-term therapy is required, as weight regain occurs when therapy is discontinued 2